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Coronavirus disease 19 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), first emerged in late 2019 and has since rapidly become
a global pandemic. SARS-CoV-2 infection causes damages to the lung and other
organs. The clinical manifestations of COVID-19 range widely from asymptomatic
infection, mild respiratory illness to severe pneumonia with respiratory failure and
death. Autopsy studies demonstrate that diffuse alveolar damage, inflammatory cell
infiltration, edema, proteinaceous exudates, and vascular thromboembolism in the
lung as well as extrapulmonary injuries in other organs represent key pathological
findings. Herein, we hypothesize that GPR4 plays an integral role in COVID-19
pathophysiology and is a potential therapeutic target for the treatment of COVID-19.
GPR4 is a pro-inflammatory G protein-coupled receptor (GPCR) highly expressed in
vascular endothelial cells and serves as a “gatekeeper” to regulate endothelium-blood
cell interaction and leukocyte infiltration. GPR4 also regulates vascular permeability
and tissue edema under inflammatory conditions. Therefore, we hypothesize that
GPR4 antagonism can potentially be exploited to mitigate the hyper-inflammatory
response, vessel hyper-permeability, pulmonary edema, exudate formation, vascular
thromboembolism and tissue injury associated with COVID-19.
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INTRODUCTION
COVID-19 first emerged in Wuhan, China in December 2019 and has rapidly become a global
pandemic with confirmed cases in more than 200 countries and regions. By November 5, 2020,
nearly 48 million confirmed cases and over 1.2 million deaths have been reported around the world
(1). The pandemic is continuing to spread andmore confirmed cases andCOVID-related deaths are
reported every day. In addition to the staggering number of human casualties and as a global effort
to stop the pandemic, social distancing, stay-at-home orders, and closure of schools and businesses
have caused enormous societal burdens and economic losses. Development of effective vaccines and
therapeutics is critical to curb the pandemic and save the lives of patients afflicted by COVID-19.
For COVID-19 patients, disease severities span from asymptomatic infection, mild respiratory
illness to severe pneumonia with respiratory failure and death (2–4). In a study of 44,415 cases in
China, 81% of patients had mild symptoms, 14% had severe symptoms and 5% had critical disease
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manifestations (5). The worldwide mortality rate
is approximately 2.5% among the confirmed cases
(1,221,781/47,930,397 as of November 5, 2020) (1), with
a higher mortality rate in elderly patients and those with
underlying conditions such as hypertension, diabetes, and
cardiovascular disease.
The pathophysiology of COVID-19 is not completely
understood. SARS-CoV-2 infects a wide range of cells, including
type II pneumocytes, vascular endothelial cells, pericytes,
macrophages, T cells, cardiomyocytes, enterocytes, kidney
epithelial cells and podocytes, all of which express the SARS-
CoV-2 receptor ACE2 (angiotensin converting enzyme 2) (4,
6). Airway epithelial cells infected by SARS-CoV-2 trigger an
inflammatory response, with production of increased levels
of cytokines and chemokines that stimulate the infiltration
of neutrophils, monocytes, and lymphocytes into the lung
and other target organs (4, 6). Autopsy studies of patients
succumbing to COVID-19 have revealed some key pathological
findings, such as diffuse alveolar damage, inflammatory cell
infiltration, pulmonary edema, proteinaceous exudates, and
vascular thromboembolism in the lung, which potentially
contribute to disease severity, acute respiratory distress syndrome
(ARDS) and respiratory failure in the patients (7–9). In addition
to lung injuries, COVID-19 complications also include impaired
function of the liver, kidney, heart, brain, and coagulation system
(4, 6, 10).
HYPOTHESIS
We propose that GPR4 is involved in COVID-19
pathophysiology and can be exploited as a potential therapeutic
target for COVID-19. GPR4 is a pro-inflammatory GPCR
that regulates endothelial cell adhesion, leukocyte infiltration,
blood vessel permeability, and angiogenesis (11–20). GPR4
is expressed in various tissues, with high expression in the
lung, heart, and kidney (21, 22). The cell types predominantly
expressing GPR4 are vascular endothelial cells and GPR4 gene
expression is also found in other cell types such as neurons,
kidney epithelial cells, osteoblasts, and chondrocytes (12, 14, 23–
26). Biochemically, GPR4 can be activated by extracellular
protons (acidosis), with acidotic conditions commonly existing
Abbreviations: ACE2, angiotensin converting enzyme 2; ARDS, acute respiratory
distress syndrome; ATF3, activating transcription factor 3; CCL2 (MCP-1),
C-C motif chemokine ligand 2 (monocyte chemoattractant protein-1); CCL3
(MIP-1α), C-C motif chemokine ligand 3 (macrophage inflammatory protein-
1α); CHOP, C/EBP homologous protein; COPD, chronic obstructive pulmonary
disease; COVID-19, coronavirus disease 19; COX2, cyclooxygenase-2; CXCL10
(IP-10), C-X-C motif chemokine ligand 10 (interferon gamma-induced protein
10); DSS, dextran sulfate sodium; ER, endoplasmic reticulum; FDA, Food and
Drug Administration; GPCR, G protein-coupled receptor; GPR4, G protein-
coupled receptor 4; IBD, inflammatory bowel disease; ICAM-1, Intercellular
Adhesion Molecule 1; ICU, intensive care unit; IgG, immunoglobulin G; IL,
interleukin; iNOS, inducible nitric oxide synthase; KO, knockout; MMP, matrix
metalloproteinase; NF-κB, nuclear factor kappa-light-chain-enhancer of activated
B cells; PGE2, prostaglandin E2; pH, potential of hydrogen; RAAS, renin-
angiotensin-aldosterone system; SARS-CoV-2, severe acute respiratory syndrome
coronavirus 2; TNF-α, tumor necrosis factor-α; VCAM-1, vascular cell adhesion
molecule 1; VEGF, vascular endothelial growth factor.
in inflamed tissues due to hypoxia and glycolytic cell metabolism
(27, 28). Importantly, genetic and pharmacological inhibition
of GPR4 alleviates inflammatory responses, reduces leukocyte
infiltration, and decreases tissue edema in several animal models
of inflammatory disorders including arthritis, inflammatory
bowel disease, chronic obstructive pulmonary disease (COPD),
and ischemic diseases (14, 15, 17–20, 29). Many of the GPR4-
regulated inflammatory processes described above share cardinal
pathological features observed in COVID-19 patients (7–9).
Therefore, we hypothesize that GPR4 plays a role in COVID-19
pathophysiology and GPR4 antagonism is a potential therapeutic
approach to mitigate COVID-19 complications.
EVALUATION OF THE HYPOTHESIS
Does GPR4 Play a Role in the
Pathophysiology of COVID-19?
Pathophysiology of Inflammatory Responses in
COVID-19
COVID-19 is caused by the infection of SARS-CoV-2, a novel
β-coronavirus sharing ∼88% and ∼80% sequence homology
with the bat derived SARS-like coronaviruses and SARS-CoV,
respectively (30). Similar to SARS-CoV, the spike glycoprotein
(S protein) of SARS-CoV-2 binds to cell surface ACE2 receptors
to gain entry into cells (4, 6). In the early stage of disease,
SARS-CoV-2 targets the respiratory system, infecting nasal and
bronchial epithelial cells and lung pneumocytes and stimulating
inflammatory responses in these cells. Consequently, the infected
cells produce increased levels of cytokines and chemokines, such
as interleukin-6 (IL-6), IL-1, TNF-α, CXCL10 (IP-10), CCL2
(MCP-1), and CCL3 (MIP-1α). The cytokines and chemokines,
in turn, induce massive infiltration of leukocytes into the lung.
The accumulation of neutrophils, monocytes, and macrophages
in the lung further increases the production of cytokines
and chemokines, generating a vicious cycle of inflammation.
Excessive production of cytokines can lead to “cytokine storm,”
acute respiratory distress syndrome (ARDS), tissue injury, multi-
organ failure, and death in critically ill COVID-19 patients (4, 6).
Besides airway epithelial cells, SARS-CoV-2 also infects many
other types of cells expressing the ACE2 receptor, such as vascular
endothelial cells and pericytes (4, 6, 10). SARS-CoV-2 infection of
lung microvascular endothelial cells aggravates the inflammatory
response. Endothelial cells function as a physiological interface
to interact with leukocytes and platelets. Pulmonary endothelial
and epithelial barriers are critical for the regulation of gas
exchange and immune cell recruitment in the lung. SARS-
CoV-2 infection of alveolar epithelial cells and pulmonary
endothelial cells can cause cell death and stimulate inflammatory
responses. Consequently, disruption of pulmonary endothelial
and epithelial barriers leads to excessive leukocyte infiltration
into the lung, plasma fluid flooding into interstitial and alveolar
spaces (i.e., permeability edema), shortness of breath, hypoxemia,
pneumonia, and ARDS in COVID-19 patients.
In addition to the hyper-inflammation and damage to
pulmonary epithelial and endothelial barriers, vascular
thromboembolism in the lung and other organs is also a
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common complication observed in severe COVID-19 patients
that is associated with fatal outcomes. In a study of 184
patients admitted to the intensive care unit (ICU), thrombotic
complications were observed in 31% of the patients (31).
Autopsy studies of the lungs from seven patients who died
from COVID-19 showed widespread thrombosis in pulmonary
vessels and microthrombi in alveolar capillaries (32). Increased
new blood vessel growth (angiogenesis) was also observed in
the lungs of these patients (32). Vascular thromboembolism
is closely associated with mortality in COVID-19 patients.
Predisposition to thromboembolism is believed to be due to
excessive inflammation and coagulopathy in COVID-19 patients
(31, 32).
Extrapulmonary complications of COVID-19 have been
observed in multiple organ systems, such as the cardiovascular,
hematological, gastrointestinal, renal, endocrine, dermatological
and neurological systems (4, 6, 10). While COVID-19 is caused
by SARS-CoV-2 infection, the host inflammatory response also
plays critical roles in the pathophysiology of the disease. Overall,
SARS-CoV-2 infection-induced direct cytotoxicity, hyper-
inflammation, endothelial cell dysfunction, thromboembolism,
cytokine-release syndrome, and dysregulation of the renin-
angiotensin-aldosterone system (RAAS) are considered as
the major mechanisms responsible for systemic COVID-19
complications in multiple organ systems (4, 6, 10).
How Is GPR4 Potentially Involved in the
Pathophysiology of COVID-19?
As described above, hyper-inflammatory responses in patients
with increased levels of cytokines, chemokines, leukocyte
infiltration, vascular permeability, tissue edema, endothelialitis,
and thromboembolism represent some key pathophysiological
features in COVID-19 (4, 6). Herein, we evaluate the potential
involvement of GPR4 in the pathophysiology of COVID-19.
GPR4 is highly expressed in vascular endothelial cells and
has emerged as a key regulator of inflammatory responses
(11–20, 27). As a proton-sensing GPCR, GPR4 can be
activated by acidosis which is a microenvironment hallmark
of numerous pathological conditions such as inflammation,
ischemia, and tumors (27, 28). Activation of GPR4 by
acidosis stimulates the expression of inflammatory chemokines,
cytokines, adhesion molecules and the NF-κB pathway in
endothelial cells, increases endothelium-leukocyte adhesion, and
facilitates leukocyte infiltration (11–16, 20). Moreover, activation
of GPR4 by acidosis promotes the endoplasmic reticulum (ER)
stress response and apoptosis of endothelial cells (12, 13, 33).
Multiple lines of evidence support a pro-inflammatory role of
GPR4 in various pathological conditions (11–20, 27, 29). Using
GPR4 knockout (KO) mice, studies demonstrated that GPR4
deletion reduces inflammation in mouse colitis models (14, 19).
In the dextran sulfate sodium (DSS)-induced acute colitis mouse
model, GPR4 deletion ameliorates intestinal inflammation (14).
The indicators of disease severity, such as body weight loss,
mesenteric lymph node expansion, colon shortening, fecal
diarrhea score, and intestinal histopathology, are alleviated in
the GPR4 KO mice compared to wild-type mice. GPR4 deletion
reduces the expression of endothelial adhesion molecules E-
selectin and VCAM-1 in the colon of the DSS-induced colitis
mice (14). Another study also demonstrated that GPR4 deletion
alleviates intestinal inflammation in the DSS-induced colitis and
the IL10-/- spontaneous colitis mouse models (19). Interestingly,
GPR4 mRNA is over-expressed by approximately 5-fold in
the inflamed intestinal lesions of inflammatory bowel disease
(IBD) patients when compared to normal intestinal tissues (14).
Furthermore, in the tourniquet cuff-induced hindlimb ischemia-
reperfusion mouse model, GPR4 deletion reduces inflammatory
response, leukocyte infiltration, vascular permeability, tissue
edema and proteinaceous exudate formation in the limb
tissue (20).
Based on its biological functions, GPR4 can potentially
regulate multiple aspects of COVID-19 pathophysiology
(Figure 1). SARS-CoV-2 infection of lung epithelial cells and
endothelial cells induces inflammatory responses in these
cells with increased expression of cytokines and chemokines
(4, 6). As the disease severity of COVID-19 progresses,
alveolar epithelial and endothelial barriers become disrupted,
oxygen/carbon dioxide exchange is impaired, and the lung
tissues become hypoxic. The pH of inflammatory and hypoxic
tissues is acidic due to reduced oxygen levels, glycolytic cell
metabolism, and proton accumulation (27, 28, 34–36). In
addition to acidotic pH in inflamed and hypoxic tissues,
respiratory and metabolic acidosis is a common complication
observed in COVID-19 patients, especially in patients with
severe disease (37). Also, COVID-19 may aggravate ketoacidosis
in diabetes patients and cause kidney injuries, leading to
metabolic acidosis in patients (38–40). As a proton-sensing
GPCR, GPR4 is optimally activated under acidic extracellular
pH (6.4–6.9) and partially activated at physiological pH 7.4
(41, 42). As described above, activation of GPR4 increases the
expression of inflammatory adhesion molecules, chemokines,
and cytokines in vascular endothelial cells, which can in
turn enhance leukocyte infiltration (11, 12, 14, 16). Increased
inflammation and adhesiveness of endothelial cells can be
prothrombotic and stimulate the adhesion and aggregation
of platelets and leukocytes (43). Moreover, activation of
GPR4 augments paracellular gap formation and permeability
of endothelial cells, which can lead to fluid accumulation
and edema in the tissues (17, 18, 20). All these biological
functions of GPR4 are highly relevant to COVID-19 patient
pathophysiology, including the hyper-inflammatory response,
leukocyte infiltration, blood vessel leakage, pulmonary edema,
and vascular thromboembolism (4, 6). Moreover, GPR4 gene
expression is up-regulated in COVID-19 patient samples. A
recent study used RNA sequencing (RNA-Seq) to identify
differentially expressed genes (DEGs) in lung and colon samples
from patients succumbing to COVID-19 (44). Compared
to normal lung and colon samples, GPR4 mRNA levels
were increased by 2.3-fold (p = 3.04E-06) and 3.9-fold
(p = 0.0074), respectively, in COVID-19 patient lung and
colon samples. The up-regulation of GPR4 gene expression
in COVID-19 patient tissues may further aggravate the
GPR4-mediated pro-inflammatory effects and contribute to
COVID-19 pathophysiology.
Frontiers in Medicine | www.frontiersin.org 3 January 2021 | Volume 7 | Article 626796
Yang et al. Role of GPR4 in COVID-19
FIGURE 1 | A hypothetical model to depict the roles of GPR4 in COVID-19 pathophysiology and the inhibition of GPR4 as a potential approach to mitigate COVID-19
complications.
Can GPR4 Antagonism Provide
Therapeutic Benefits for the Treatment of
COVID-19?
Current Treatment Approaches for COVID-19
Current therapeutic modalities for COVID-19 mainly include
anti-viral drugs, antibodies, and anti-inflammatory agents. A
randomized clinical trial demonstrated that the treatment
with the antiviral drug remdesivir accelerates the recovery of
hospitalized COVID-19 patients (11 vs. 15 days, compared to
placebo, P < 0.001) and also shows a trend of survival benefit
(a mortality rate by 14 days of 7.1 vs. 11.9%, compared to placebo,
P > 0.05) (45). However, another randomized clinical trial failed
to demonstrate significant therapeutic benefits of remdesivir
in patients with severe COVID-19 (46). Transfusion with
convalescent plasma containing antiviral neutralizing antibodies
demonstrates signs of improvement in critically ill COVID-19
patients. In 35,322 severely ill COVID-19 patients (52.3% in
the ICU and 27.5% receiving mechanical ventilation) transfused
with convalescent plasma on the Expanded Access Program, a
decrease of 30-day mortality was observed in patients transfused
within 3 days of COVID-19 diagnosis compared to 4 or more
days after diagnosis (21.6 vs. 26.7%, p < 0.0001), suggesting
a potential benefit of early intervention. Also, the mortality of
the patients receiving high IgG plasma was lower than that of
the patients receiving low IgG plasma (47). However, a phase
II randomized trial with hospitalized, moderately ill COVID-19
patients (235 in the intervention arm and 229 in the control
arm) failed to demonstrate any reduction in mortality with
convalescent plasma treatment (14.5% in the intervention arm
vs. 13.5% in the control arm) (48). In a phase II randomized
trial involving outpatients with mild or moderate COVID-19,
the SARS-CoV-2 neutralizing antibody LY-CoV555 was shown
to decrease viral load and reduce the percentage of patients
who had a COVID-19 related hospitalization or emergency
department visit (1.6 vs. 6.3%, compared to placebo) (49). In
addition to antiviral drugs, convalescent plasma and neutralizing
antibodies, studies have evaluated the therapeutic effects of anti-
inflammatory agents in COVID-19 because hyper-inflammatory
responses (cytokine storm) are observed in some COVID-
19 patients. The Recovery trial showed that dexamethasone
reduces mortality rate in hospitalized COVID-19 patients within
28 days (22.9% in the dexamethasone group vs. 25.7% in
the usual care group, P < 0.001), with a trend of more
benefits in patients receiving invasive mechanical ventilation or
oxygen (50). Tocilizumab, a monoclonal antibody targeting the
interleukin-6 receptor (IL-6R), demonstrated clinical benefits in
some COVID-19 patients by reducing the hyper-inflammatory
responses; however, it was also observed that some patients
were refractory to tocilizumab treatment (51, 52). This is likely
because a multitude of inflammatory cytokines and molecules
are involved in the hyper-inflammatory response. In a recent
open-label cohort study of severe COVID-19 patients with
systemic hyper-inflammation, blockade of IL-6R with sarilumab
did not significantly improve overall clinical outcomes or reduce
mortality compared to standard of care, but sarilumab treatment
was associated with faster recovery in a subset of patients (53).
Overall, current therapeutic approaches for COVID-19 patients
with severe disease are not particularly effective. It is critical to
fully understand the pathophysiology of COVID-19 and develop
more effective therapeutics to significantly reduce COVID-19
mortality and morbidity.
Can GPR4 Antagonism Mitigate COVID-19
Complications?
Recently, GPR4 specific inhibitors have been developed and
their biological effects have been characterized (Table 1).
Derivatives of imidazo-pyridine and pyrazolopyrimidine
compounds have been identified as novel GPR4 antagonists
(16–18, 54). Studies have shown that GPR4 antagonists
reduce inflammation in the antigen-induced arthritis rat
model, the DSS-induced acute colitis mouse model, and the
short-term emphysema-exacerbation COPD mouse model as
well as alleviate inflammatory pain in the complete Freund’s
adjuvant-induced hyperalgesia rat model (15, 17, 18, 29). In the
DSS-induced acute colitis model, GPR4 antagonist 13 (NE-52-
QQ57) ameliorates intestinal inflammation and decreases the
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TABLE 1 | Biological effects of GPR4 antagonists in vitro and in vivo.
Experimental models GPR4 antagonist effects References
Endothelial cell culture (in vitro): microarray, qRT-PCR, and
Western blot analyses; endothelial cell adhesion, gap
formation, and permeability assays
Inhibiting the expression of inflammatory chemokines, cytokines, adhesion molecules,
COX2, NF-κB pathway genes, and ER stress genes in endothelial cells in response to
acidosis; Reducing endothelial cell-leukocyte adhesion; Decreasing endothelial
paracellular gap formation and permeability.
(12, 13, 16, 20)
Chondrocyte culture (in vitro): SW1353 chondrocyte cell
line; RT-PCR, Western blot, and ELISA analyses; nitric oxide
assay; NF-κB reporter assay
Inhibiting the advanced glycation end products (AGEs)-induced expression of
inflammatory molecules such as TNF-α, IL-1β, IL-6, iNOS, nitric oxide (NO), COX2,
and PGE2; Inhibiting the expression of matrix metalloproteinase (MMP)-3 and
MMP-13; Suppressing the NF-κB pathway.
(24)
Mouse myocardial infarction model (in vivo): Kaplan–Meier
survival analysis
Prolonging mouse survival in the myocardial infarction model with permanent left
anterior descending coronary artery ligation.
(54)
Rat antigen induced arthritis model (in vivo): rats sensitized
with methylated bovine serum albumin (mBSA)/complete
Freund’s adjuvant (CFA)
Reducing knee swelling, inflammatory cell infiltration, joint damage, and proteoglycan
loss, comparable to the effects of dexamethasone.
(17, 18)
Rat hyperalgesia model (in vivo): inflammatory pain induced
by CFA
Demonstrating antinociceptive effects, comparable to diclofenac, in the complete
Freund’s adjuvant (CFA) induced hyperalgesia rat model.
(17, 18)
Mouse angiogenesis model (in vivo): porous tissue
chambers filled with VEGF
Inhibiting VEGF-induced angiogenesis. (17, 18)
Mouse and rat cardiorespiratory models (in vivo): evaluation
of the GPR4 antagonist NE 52-QQ57 on cardiorespiratory
effects in rodents
Having no effects on hemodynamics, cerebral blood flow, and blood oxygen level
dependent responses in anesthetized rats; Causing a small reduction in the ventilatory
response to 5 and 10% CO2 in awake but not in anesthetized mice and rats; Having
no serious adverse effects on cardiovascular and respiratory systems in rodents.
(23)
Mouse colitis model (in vivo): DSS-induced colitis model
studied by gene expression and histopathologic analyses
Alleviating intestinal inflammation in the DSS-induced colitis mouse model;
Attenuating leukocyte infiltration in the colon; Reducing mesenteric lymph node
enlargement; Decreasing the expression of VCAM-1, E-selectin, and TNF-α in colon
blood vessels.
(15)
Mouse hindlimb ischemia-reperfusion model (in vivo):
evaluated by gene expression and histopathologic analyses
Suppressing the inflammatory response in mouse hindlimb post the
tourniquet-induced ischemia-reperfusion; Reducing tissue edema, inflammatory
exudate formation, and leukocyte infiltration; Decreasing the expression of VCAM-1,
and E-selectin in the hindlimb tissue post ischemia-reperfusion.
(20)
Mouse COPD model (in vivo): porcine pancreatic elastase
and lipopolysaccharide induced emphysema-exacerbation
model
Attenuating inflammation in the short-term emphysema-exacerbation COPD mouse
model; Reducing lung edema and permeability; Decreasing leukocyte infiltration,
inflammatory cytokine expression, mucin production, and protease (MMP9 and
MMP12) expression in the lung.
(29)
expression of TNF-α in the inflamed mouse colon tissues (15).
In the COPD mouse model, treatment with GPR4 antagonist
reduces leukocyte infiltration, inflammatory cytokine expression,
mucin production, and protease expression in the lung (29). Like
GPR4 genetic knockout mice, GPR4 antagonists exhibit anti-
angiogenic effects and attenuate inflammatory responses, tissue
edema and exudate formation (17, 18, 20). Additionally, GPR4
antagonists reduce the expression of inflammatory chemokines,
cytokines, adhesion molecules, NF-κB pathway genes, and
stress responsive genes, such as IL-1, IL-8, CXCL1, CXCL2,
CCL2, CCL7, VCAM-1, ICAM-1, E-selectin, RELB, COX2,
ATF3, and CHOP, in cultured endothelial cells (12, 13, 16).
Treatment with the GPR4 antagonist NE-52-QQ57 inhibits the
expression of inflammatory molecules including TNF-α, IL-1β,
IL-6, iNOS, nitric oxide (NO), COX2, and PGE2 in cultured
chondrocytes (24). Furthermore, studies have demonstrated
that genetic knockout and pharmacological inhibition of GPR4
protect mice from ischemic injury in the myocardial infarction,
renal ischemia-reperfusion, and hindlimb ischemia-reperfusion
mouse models (20, 54, 55).
Based on the effects of GPR4 antagonists in other disease
models, inhibition of GPR4 can be explored as a novel
approach to mitigate COVID-19 complications. GPR4
antagonists potentially target several key aspects of COVID-
19 pathophysiology (Figure 1). First, GPR4 antagonists may
inhibit inflammatory responses and leukocyte infiltration in the
lung and other affected organs of COVID-19 patients. Hyper-
inflammatory responses and massive leukocyte infiltration
are observed in COVID-19 patients exhibiting severe disease
symptoms (4, 6). Inhibition of GPR4 can suppress the expression
of inflammatory adhesion molecules, chemokines, and cytokines
in vascular endothelial cells and subsequently decrease leukocyte-
endothelium adhesion, extravasation and inflammatory
responses (11–20, 29). Second, GPR4 antagonists may reduce
vascular leakage, tissue edema and inflammatory exudate
formation in COVID-19. Increased vascular permeability and
disruption of epithelial and endothelial barriers in COVID-19
patients result in fluid accumulation and exudate formation in
the lung, with impaired gas exchange and hypoxemia (4, 6).
As shown in the hindlimb ischemia-reperfusion, arthritis,
and COPD animal models, inhibition of GPR4 can reduce
vessel permeability and tissue edema (17, 18, 20, 29). Third,
GPR4 antagonists may attenuate vascular thromboembolism in
COVID-19. Due to coagulopathy, endothelial dysfunction and
hyper-inflammatory responses, vascular thromboembolism is a
common complication in severely ill COVID-19 patients (31, 32).
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Activation of GPR4 increases endothelial cell adhesiveness and
blood cell-endothelium interactions (11, 12, 16). Inhibition
of GPR4 may lessen inflammatory response, blood cell-
endothelium adhesion and aggregation, and thromboembolism
(43). Fourth, GPR4 antagonists may decrease angiogenesis in
COVID-19. While the pathophysiological significance is still
unclear, angiogenesis is increased in the lung of COVID-19
patients (32). Inhibition of GPR4 hinders blood vessel formation
by modulating the VEGF pathway (17, 18, 56). GPR4 antagonists
can potentially curtail angiogenesis in COVID-19. Fifth, GPR4
antagonists may alleviate pain associated with COVID-19.
Muscle aches, sore throat, headache, and chest pain are common
symptoms of COVID-19. GPR4 is expressed in nociceptors such
as dorsal root ganglion neurons and consequently aggravates
inflammatory pain (17, 18, 57). Inhibition of GPR4 can
potentially mitigate inflammatory pain in COVID-19 patients.
DISCUSSION
SARS-CoV-2 infection in the lung and other organs cause
cellular injury and inflammatory responses in COVID-19
patients (4, 6, 10). Clinical manifestations of COVID-19
range widely from asymptomatic carriers to severe disease
and death. Based on the current incomplete understanding
of COVID-19 pathophysiology, therapeutic strategies have
been directed toward anti-viral, anti-inflammatory, and anti-
coagulatory agents. The applications of remdesivir, convalescent
plasma, dexamethasone, tocilizumab, and low molecular weight
heparin have achieved limited success in severely ill COVID-19
patients (4, 6). Because various factors are involved in COVID-
19 pathophysiology, combination therapy targeting both the
SARS-CoV-2 virus and the host inflammatory response may
be required to achieve optimal treatment outcomes. A better
understanding of COVID-19 pathophysiology will help develop
novel therapeutic approaches.
We hypothesize that GPR4 plays an integral role in COVID-
19 pathophysiology and inhibition of GPR4 can be explored
as a novel approach to mitigate COVID-19 complications. G
protein-coupled receptors (GPCRs) are the largest family of
cell surface receptors that serve as pharmacological targets
of ∼34% of all FDA approved drugs (58). GPR4 antagonists
have recently been developed and characterized. Consistent
with its pro-inflammatory function, GPR4 inhibition by
its antagonists alleviates inflammation, edema, and pain in
preclinical disease models (15, 17, 18, 20, 29). To evaluate the
potential therapeutic effects of GPR4 antagonists in COVID-
19, the inhibitors can first be tested in preclinical animal
models predisposed to infection with SARS-CoV-2, such as the
human angiotensin-converting enzyme 2 (hACE2) transgenic
mice and hamsters (59, 60). In addition to inflammatory
responses, the effects of GPR4 antagonists on other COVID-19
complications such as blood vessel permeability, lung edema,
vascular thromboembolism, and pain can also be evaluated in
these preclinical animal models.
With regard to the safety profile and adverse effects of the
GPR4 antagonists, an oral dose of 30–100 mg/kg (b.i.d.) is well
tolerated in preclinical animal models without overt adverse
effects (15, 17, 18, 20, 23, 29). The optimized GPR4 antagonist
13 (NE 52-QQ57) has no documented serious adverse effects
on the cardiovascular and respiratory systems in mouse and
rat models (23). Specifically, the GPR4 antagonist 13 (NE 52-
QQ57) is selective for the GPR4 receptor and has no or minimal
effects on other proton-sensing GPCRs or the common off-
targets such as the H3 receptor and hERG channel (17). GPR4
antagonist 13 (NE 52-QQ57) does not affect hemodynamics,
blood oxygen level dependent responses, or cerebral blood
flow in rodents (23). It causes a slight reduction in the
ventilatory response to 5 and 10% CO2 in non-anesthetized but
not in anesthetized mice and rats (23). Moreover, phenotypic
observations from GPR4 knockout mice indicate several facets of
GPR4 functions. A small percentage of GPR4-null mice exhibit
perinatal complications (61). Upon acid overload, GPR4-null
mice have slightly decreased renal acid excretion (26). GPR4 is
also involved in carbon dioxide chemosensing (62). Deletion of
GPR4 is associated with lower blood pressure, lower binding
to angiotensin II receptor, and increased insulin sensitivity (63,
64); these aspects are of particular interest as hypertension and
diabetes are risk factors associated with COVID-19 mortality
(4). The functional characteristics from knockout studies should
be closely monitored when GPR4 antagonists are applied in
vivo, although the biological effects from genetic knockout
are not necessarily identical to pharmacological inhibition.
Overall, the GPR4 antagonists exhibit a good pharmacological
profile and oral bioavailability in preclinical animal models,
providing a foundation for therapeutic evaluation in COVID-19
disease models.
Due to the complex pathophysiology of COVID-19,
combination therapy is likely needed to achieve optimal
treatment outcomes in COVID-19 patients with severe disease.
In this respect, there are several strategies to apply GPR4
antagonists in combination with other therapeutic agents.
One strategy is to combine GPR4 antagonists with anti-
viral agents such as remdesivir to target both SARS-CoV-2
replication and the host hyper-inflammatory responses. Another
strategy is to combine GPR4 antagonists with other anti-
inflammatory agents such as dexamethasone, of which GPR4
antagonists target the endothelium-leukocyte interactions
and dexamethasone targets immune cells. These strategies
can be assessed in preclinical COVID-19 animal models and
eventually patients. In summary, our central hypothesis is that
GPR4 is a pro-inflammatory receptor involved in COVID-19
pathophysiology and GPR4 antagonists, whether as a single
therapeutic agent or in combination with other agents, can
be explored as a potential therapeutic approach to mitigate
COVID-19 complications and may also find applications in
other related diseases.
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